Barriers to resection following neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma: A national and local perspective

Documenti analoghi

• The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy
  di: Elizabeth L. Carpenter, et al.
  Pubblicazione: (2024)
• Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi‐institutional analysis
  di: Haleh Amirian, et al.
  Pubblicazione: (2024)
• Neoadjuvant chemotherapy for resectable gastric cancer is associated with better outcomes than neoadjuvant chemoradiation
  di: Hideo Takahashi, et al.
  Pubblicazione: (2024)
• Neoadjuvant chemotherapy is associated with improved disease‐free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection
  di: Dustin L. Dillon, et al.
  Pubblicazione: (2024)
• Use of neoadjuvant paclitaxel in breast angiosarcoma—Impact on surgical resection and response rates
  di: Luke V. Selby, et al.
  Pubblicazione: (2024)